Literature DB >> 30112581

A brief report on the clinical trial on neural mobilization exercise for joint pain in patients with rheumatoid arthritis.

Yan Nok Lau1, Joseph Ng1, Shan Yee Lee1, Lam Chin Li1, Cheuk Man Kwan1, Sin Ming Fan1, Bernard Pui Lam Leung2, Chi Ngai Lo3,4.   

Abstract

BACKGROUND: In rheumatoid arthritis (RA) synovitis, activation of synoviocytes and infiltration of adaptive immune cells leads to synovial hyperplasia and joint swelling. Under the elevated extra-neural pressure, free nerve endings release neuropeptides, calcitonin gene-related peptide, and substance P, thus promoting neurogenic inflammation.
OBJECTIVE: This study aimed to assess the effect of therapeutic neural mobilization (NM) exercises targeting the nervous system on disease impact in RA patients.
METHODS: A total of 21 RA patients were randomized into NM (n = 11) and control (n = 10) groups. NM group patients performed NM exercises targeting the median, musculocutaneous, femoral, and saphenous nerve, as well as the entire nervous system twice daily for 4-8 weeks. Control RA patients performed gentle joint mobilization exercises targeting the same joints. Primary outcome was the change in pre-/post-treatment score in the validated Rheumatoid Arthritis Impact of Disease (RAID). Secondary outcome was erythrocyte sedimentation rate (ESR).
RESULTS: There were no significant differences between the groups at baseline. No adverse events were observed and compliance was over 90%. Post-treatment, favorable changes were observed in the NM group RAID score: -5.1 vs. -0.8; weighted RAID score: -0.79 vs. -0.15. ESR was reduced in the NM group, albeit non-significantly. Regarding the RAID score domains, the NM group demonstrated significant improvements in pain and coping.
CONCLUSION: The current data indicate a beneficial effect of NM exercises on pain and self-efficacy in our RA patients. Larger clinical studies are warranted to determine the clinical effectiveness of NM as a treatment for pain for RA patients and simultaneously address immune and neuropeptide modulation through NM.

Entities:  

Keywords:  Autoimmune diseases; Blood sedimentation; Nervous system; Physiotherapy; Questionnaires

Mesh:

Year:  2019        PMID: 30112581     DOI: 10.1007/s00393-018-0521-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  4 in total

1.  Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.

Authors:  Nadia M T Roodenrijs; Attila Hamar; Melinda Kedves; György Nagy; Jacob M van Laar; Désirée van der Heijde; Paco M J Welsing
Journal:  RMD Open       Date:  2021-01

2.  EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.

Authors:  György Nagy; Nadia M T Roodenrijs; Désirée van der Heijde; Jacob M van Laar; Paco M J Welsing; Melinda Kedves; Attila Hamar; Marlies C van der Goes; Alison Kent; Margot Bakkers; Polina Pchelnikova; Etienne Blaas; Ladislav Senolt; Zoltan Szekanecz; Ernest H Choy; Maxime Dougados; Johannes Wg Jacobs; Rinie Geenen; Johannes Wj Bijlsma; Angela Zink; Daniel Aletaha; Leonard Schoneveld; Piet van Riel; Sophie Dumas; Yeliz Prior; Elena Nikiphorou; Gianfranco Ferraccioli; Georg Schett; Kimme L Hyrich; Ulf Mueller-Ladner; Maya H Buch; Iain B McInnes
Journal:  Ann Rheum Dis       Date:  2021-08-18       Impact factor: 19.103

Review 3.  Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis.

Authors:  Judit Majnik; Noémi Császár-Nagy; Georgina Böcskei; Tamás Bender; György Nagy
Journal:  Front Med (Lausanne)       Date:  2022-08-29

4.  Effectiveness of neural mobilization on pain intensity, disability, and physical performance in adults with musculoskeletal pain-A protocol for a systematic review of randomized and quasi-randomized controlled trials and planned meta-analysis.

Authors:  Frederico Mesquita Baptista; Eduardo Brazete Cruz; Vera Afreixo; Anabela G Silva
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.